ESMO 2022: Cemiplimab Yields Complete Response in Cutaneous Squamous Cell Carcinoma
The anti-programmed cell death 1 monoclonal antibody may dramatically improve quality of life for cSCC patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.